HCW Biologics restates Q1 EPS, cutting net income attributable to common shareholders by USD 728,000
HCWB•Cash flow and balance sheet unchanged
Total net income stayed USD 3.47 million; cash flows, assets, liabilities, and equity were unchanged since the adjustment only reallocated earnings.
Restated first-quarter results correct EPS treatment
HCW Biologics filed restated quarterly results for the three months ended March 31, 2026 in a Form 10-Q/A.
The restatement corrected earnings-per-share under ASC 260, treating certain common warrants as participating securities under the two-class method.
Impact on net income attributable to common stockholders
Net income attributable to common stockholders fell by about USD 728,000 to USD 1.26 million.
Basic and diluted EPS dropped by USD 0.8 to USD 1.39, reflecting a one-for-six reverse stock split effective June 30, 2026.
